Profit

Lupin Gets USFDA Nod To Market Cancer Drug

 Share
EMAIL
PRINT
COMMENTS
Lupin Gets USFDA Nod To Market Cancer Drug
New Delhi: Pharma major Lupin Ltd has received final approval from the USFDA to market sodium sulfate, potassium sulfate, magnesium sulfate oral solution used in treatment of a form of cancer.

In a BSE filing, Lupin said "it has received final approval for its sodium sulfate, potassium sulfate, magnesium sulfate oral solution, 17.5 g/3.13 g/ 1.6 g per ounces from the United States Food and Drug Administration (FDA) to market a generic version of Braintree Laboratories' Suprep Bowel Prep Kit."

Lupin said it will commence promoting the product shortly. The approved product is indicated for cleansing of the colon in preparation of colonoscopy in adults. Suprep Bowel Prep Kit had US sales of $207.2 million.

Shares of Lupin were trading 0.58 per cent higher at Rs 1,472.30 on the BSE.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)


Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.

NDTV Beeps - your daily newsletter

................................ Advertisement ................................

................................ Advertisement ................................

................................ Advertisement ................................

Top